We are driven by the mission to improve the lives of people with cancer by transforming the efficacy of cancer surgery.
Our imaging, sensing and AI tools help surgeons to quickly and accurately detect cancer in real-time in the operating room, aiming to enhance surgical precision, improve patient outcomes, and reduce costs for healthcare systems.
Our Founder and Executive Chair, Dr David Tuch, introduces Lightpoint and our new miniature surgical probe for intra-operative cancer detection, SENSEI®.
Lightpoint announces positive clinical trial data for SENSEI® in prostate cancer surgery at the Annual Congress of the European Association of Nuclear Medicine. SENSEI® achieved 100% detection of sentinel lymph nodes in prostate cancer surgery and detected more sentinel nodes than a conventional gamma probe.
Dr Matthias Heck at the Technical University of Munich is the world's first surgeon to test SENSEI® in combination with PSMA in prostate cancer surgery.
Lightpoint and Telix agree strategic collaboration to explore how Lightpoint's innovative surgical devices and Telix's molecularly-targeted imaging agents can be used together for real-time intra-operative cancer detection.